



Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

7.28.21

TORONTO-

-

(BUSINESSWIRE)-

-

July

28,

2021-

-

Cybin

Inc.

[Our Work](#)[Investors](#)[About Us](#)

(OTCQB:
CLXPF)
("Cybin"
or
the
"Company"),
a
biotechnology
company
focused
on
progressing
psychedelic
therapeutics,
announced
today
the
pricing
of
its
previously
announced
overnight
marketed
offering

[Our Work](#)[Investors](#)[About Us](#)

an
aggregate
of
8,824,000
common
shares
in
the
capital
of
the
Company
(the
“Shares”) at
a
price
of
\$3.40
per
Share
for
total
gross
proceeds



[Our Work](#)

[Investors](#)

[About Us](#)

Cantor
Fitzgerald
Canada
Corporation
and
Canaccord
Genuity
Corp.,
as
joint
bookrunners,
co-
led
the
syndicate
of
underwriters
for
the
Offering,
which
included
H.C.
Wainwright



[Our Work](#)

[Investors](#)

[About Us](#)

LLC,
Roth
Canada,
ULC,
and
Stifel
Nicolaus
Canada
Inc.
(collectively,
the
“Underwriters”).

The
Offering
is
expected
to
close
on
or
about
August
3,
2021,



[Our Work](#)

[Investors](#)

[About Us](#)

other
date
as
the
Underwriters
and
the
Company
may
agree,
and
completion
of
the
Offering
will
be
subject
to
market
and
other
customary
conditions,
including



[Our Work](#)

[Investors](#)

[About Us](#)

the
Neo
Exchange
Inc.
(the
“**NEO
Exchange**”).

The
Company
has
granted
the
Underwriters
a
30-
day
option
to
purchase
up
to
an
additional
1,323,600



[Our Work](#)

[Investors](#)

[About Us](#)

of
the
Shares
issued
pursuant
to
the
proposed
Offering
on
the
same
terms
and
conditions
for
market
stabilization
purposes
and
to
cover
over-
allotments(the
“Over-



[Our Work](#)

[Investors](#)

[About Us](#)

The
Over-
Allotment
Option
may
be
exercised
in
whole
or
in
part
as
determined
by
the
Underwriters.

The
Company
intends
to
use
the
net

[Our Work](#)[Investors](#)[About Us](#)

the
Offering
for
general
corporate
and
working
capital
purposes.

The
Shares
will
be
offered
in
each
of
the
provinces
of
Canada,
excluding
Quebec,
pursuant



[Our Work](#)

[Investors](#)

[About Us](#)

prospectus
supplement
to
the
Company's
short
form
base
shelf
prospectus
dated
July
5,
2021
(the
"Base
Shelf
Prospectus").
The
Shares
will
not
be
offered
or



[Our Work](#)

[Investors](#)

[About Us](#)

the
United
States
or
to
U.S.
persons
except
pursuant
to
Rule
144A
or
in
such
other
manner
as
to
not
require
registration
under
the
United

[Our Work](#)[Investors](#)[About Us](#)

Act
of
1933,as
amended
(the
“U.S.
Securities
Act”).Prior
to
forming
an
investment
decision,
prospective
investors
should
read
the
Base
Shelf
Prospectus
and
the
documents
incorporated

[Our Work](#)[Investors](#)[About Us](#)

therein,
including
any
marketing
materials,
which
are
available
on
the
Company's
SEDAR
profile
available
at
www.sedar.com.

*This
news
release
shall
not
constitute
an
offer*



[Our Work](#)

[Investors](#)

[About Us](#)

*or
the
solicitation
of
an
offer
to
buy
securities
in
the
United
States,
nor
shall
there
be
any
sale
of
the
securities
in
any
jurisdiction*



Our Work

Investors

About Us

*such
offer,
solicitation
or
sale
would
be
unlawful.*

*The
securities
to
be
offered
have
not
been,
and
will
not
be
registered
under
the
U.S.
Securities*



Our Work

Investors

About Us

*under
any
U.S.
state
securities
laws,
and
may
not
be
offered
or
sold
in
the
United
States
or
to,
or
for
the
account
or
benefit*



Our Work

Investors

About Us

*persons,
absent
registration
or
an
applicable
exemption
from
the
registration
requirements
of
the
U.S.
Securities
Act
and
applicable
state
securities
laws.*

**About
Cybin**



[Our Work](#)

[Investors](#)

[About Us](#)

a
leading
biotechnology
company
focused
on
progressing
psychedelic
therapeutics
by
utilizing
proprietary
drug
discovery
platforms,
innovative
drug
delivery
systems,
novel
formulation
approaches
and
treatment
regimens



[Our Work](#)

[Investors](#)

[About Us](#)

disorders.

Cautionary

Notes

and

Forward-

Looking

Statements

Certain

statements

in

this

news

release

related

to

the

Company

are

forward-

looking

statements

and

are

prospective



[Our Work](#)

[Investors](#)

[About Us](#)

Forward-
looking
statements
are
not
based
on
historical
facts,
but
rather
on
current
expectations
and
projections
about
future
events
and
are
therefore
subject
to
risks



[Our Work](#)

[Investors](#)

[About Us](#)

which
could
cause
actual
results
to
differ
materially
from
the
future
results
expressed
or
implied
by
the
forward-
looking
statements.
These
statements
generally
can
be



Our Work

Investors

About Us

the
use
of
forward-
looking
words
such
as
“may”,
“should”,
“could”,
“intend”,
“estimate”,
“plan”,
“anticipate”,
“expect”,
“believe”
or
“continue”,
or
the
negative
thereof
or
similar



[Our Work](#)

[Investors](#)

[About Us](#)

looking
statements
in
this
news
release
include
statements
regarding
the
anticipated
closing
of
the
Offering,
the
exercise
of
the
Over-
Allotment
Option,
the
use
of



[Our Work](#)

[Investors](#)

[About Us](#)

and
the
receipt
off
applicable
regulatory
approvals,
including
the
approval
of
the
NEO
Exchange.
There
are
numerous
risks
and
uncertainties
that
could
cause
actual
results



[Our Work](#)

[Investors](#)

[About Us](#)

plans
and
objectives
to
differ
materially
from
those
expressed
in
the
forward-
looking
information.

Actual
results
and
future
events
could
differ
materially
from
those
anticipated



[Our Work](#)

[Investors](#)

[About Us](#)

information.

These

and

all

subsequent

written

and

oral

forward-

looking

information

are

based

on

estimates

and

opinions

of

management

on

the

dates

they

are

made

[Our Work](#)[Investors](#)[About Us](#)

expressly
qualified
in
their
entirety
by
this
notice.
Except
as
required
by
law,
the
Company
does
not
intend
to
update
these
forward-
looking
statements.



[Our Work](#)

[Investors](#)

[About Us](#)

no
medical,
treatment
or
health
benefit
claims
about
Cybin's
proposed
products.
The
U.S.
Food
and
Drug
Administration,
Health
Canada
or
other
similar
regulatory
authorities
have



[Our Work](#)

[Investors](#)

[About Us](#)

claims
regarding
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceutical
products.

The
efficacy
of
such
products
has
not
been
confirmed
by
approved



[Our Work](#)

[Investors](#)

[About Us](#)

is
no
assurance
that
the
use
of
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceuticals
can
diagnose,
treat,
cure
or
prevent
any



[Our Work](#)

[Investors](#)

[About Us](#)

condition.

Vigorous

scientific

research

and

clinical

trials

are

needed.

Cybin

has

not

conducted

clinical

trials

for

the

use

of

its

proposed

products.

Any

references

to



[Our Work](#)

[Investors](#)

[About Us](#)

efficacy
and
safety
of
potential
products
do
not
imply
that
Cybin
verified
such
in
clinical
trials
or
that
Cybin
will
complete
such
trials.
If
Cybin

[Our Work](#)[Investors](#)[About Us](#)

the
approvals
or
research
necessary
to
commercialize
its
business,
it
may
have
a
material
adverse
effect
on
Cybin's
performance
and
operations.

*The
NEO
Exchange.*



[Our Work](#)

[Investors](#)

[About Us](#)

*approved
nor
disapproved
the
contents
of
this
news
release
and
is
not
responsible
for
the
adequacy
and
accuracy
of
the
contents
herein.*

Contacts



[Our Work](#)

[Investors](#)

[About Us](#)

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

Cybin@kcsa.com

Lisa

M.

Wilson

In-

Site

Communications,

Inc.

lwilson@insitecony.com

Media

Contacts:

John

Kanakis

Cybin

Inc.



[Our Work](#)

[Investors](#)

[About Us](#)

[PREVIOUS POST](#)

[NEXT POST](#)



5600-100 King St W, Toronto ON
M5X 1C9

Investor Contact: ir@cybin.com

General Contact:
info@cybin.com

Our Work

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

Investors

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

About Us

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)



Copyright Cybin Corp. © 2021 . All rights reserved.

[Privacy Policy](#)